https://www.ukrmp.org.uk/latest/ukrmp2-strategic-call/
Deadline: Intention to Apply stage, deadline 11th April 2019. Full stage deadline 9th May 2019.
Amount: £300k – £600k (total budget = £3m)
Duration: Up to 3 years
Up to £3 million is available for translational research projects that will enhance the UKRMP investment to help further realise the exciting potential of regenerative medicine research.
In particular, this call is seeking to fund projects that address translational bottlenecks, such as safety science, and add value to the core programmes of the UKRMP.
This opportunity is also aimed at helping new groups connect to the Platform, and it is anticipated that the majority (60%) of funding will be allocated to principal investigators outside the current UKRMP Hubs.
The UKRMP2 strategic call will build upon the existing UKRMP investment and fund a small number of cutting-edge regenerative medicine research projects which extend and/or build on Platform capabilities in addressing the key challenges in translational regenerative medicine.
Overt connectivity to one or more of the Hubs, and complementarity to the UKRMP programme as a whole, is required for successful applications.
The challenge to be addressed, and the deliverable(s) from the project, must be clearly articulated.
This call will support pre-clinical research projects which focus on tractable challenges on the path towards translation.
While in-human studies are not anticipated under this call, bids should nevertheless clearly identify their place in the translational pathway towards clinical application.
Applications are welcome for projects which link and/or expand across core Hub science themes and/or provide interconnectivity between one or more cross-cutting areas.
The goal of the Platform is to unlock scientific knowledge and produce tools, reagents and approaches which are applicable to a broad range of diseases.
Organ or disease-based exemplars provide a necessary level of focus within the Hub programmes, and applicants under this call should similarly identify a clinical exemplar that will ultimately provide proof of concept.
In addition to current Hub exemplars (Parkinson’s disease, megakaryocytes, liver disease, cartilage, lung repair and eye disease) proposals with direct applicability to type 1 diabetes and multiple sclerosis are particularly encouraged, reflecting the key partnerships with JDRF UK and the MS Society in this call.
Supporting projects that address ‘safety’ considerations related to the development of regenerative therapeutics is a strategic priority.
Applications are particularly encouraged that focus on the development of analytical methods required for regenerative therapies relevant to the Hub and charity disease indications, for example potency assays that are credible and replicable, quantitative pre-clinical/clinical imaging technologies and marker technologies with the sensitivity and capability to answer key questions at the cellular level, cell bio-distribution, toxicity.
Additionally, bioinformatic approaches which unify or deconvolve currently available outputs to allow stop/go safety decisions are also welcomed.
The UKRMP2 strategic call includes a compulsory ‘Intention to Apply’ stage, deadline 11th April 2019.
The Intention to Apply should be top level and a maximum of two sides of A4 (Arial 11pt, 2cm margins, no less than single line spacing).
This should briefly address the key strategic needs and challenges, setting out the proposal’s aims and objectives (using the information required for the full submission as a guide to critical issues) and identify the lead and key partners of the proposed research team.
Applicants who do not submit an Intention to Apply will be ineligible to submit a full application.
This is for administrative purpose only; feedback will not be provided other than confirmation that the proposed bid is within scope and can be submitted.
Early conversations with the Hub Directors and their teams are recommended in shaping proposals.
Please ensure to read the full call details available through the links above.